To the full analysis
Gland Pharma stock: growth
GLAND.NSGland Pharma reported $683.5M in revenue for fiscal 2026, up 14.5% on the prior year, up 13.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
17.7%
per year from 2017 to 2026, per share 16.9%
Earnings (Annual rate)
10.6%
per year from 2017 to 2026, per share 9.9%
Free cash flow (Annual rate)
8.3%
per year from 2017 to 2026, per share 7.6%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2017 | |
|---|---|---|
| Revenue | 13.2% | 17.7% |
| Revenue per share | 12.3% | 16.9% |
| Earnings | 0.6% | 10.6% |
| Earnings per share | −0.2% | 9.9% |
| Free cash flow | 14.5% | 8.3% |
| Free cash flow per share | 13.6% | 7.6% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2017 | $157.22M | $43.97M | $38.29M |
| 2018 | $172.18M | $34.12M | $12.43M |
| 2019 | $217.28M | $48.03M | $5.26M |
| 2020 | $279.88M | $82.15M | $53.81M |
| 2021 | $368.06M | $105.97M | $39.98M |
| 2022 | $467.74M | $128.79M | $28.55M |
| 2023 | $385.25M | $83.02M | $14.97M |
| 2024 | $602.09M | $82.1M | $64.5M |
| 2025 | $596.97M | $74.25M | $56.35M |
| 2026 | $683.5M | $109.19M | $78.71M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 12 Nov 2026, previously Neutral
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.